11/24
07:19 am
iova
Iovance Biotherapeutics (NASDAQ:IOVA) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
High
Report
Iovance Biotherapeutics (NASDAQ:IOVA) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
11/21
05:15 pm
iova
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
High
Report
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
11/12
03:15 pm
iova
Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around? [Yahoo! Finance]
Neutral
Report
Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around? [Yahoo! Finance]
11/11
01:33 pm
iova
Iovance Biotherapeutics: Base-Case Q3 Report Keeps 'Show Me' Mode [Seeking Alpha]
Low
Report
Iovance Biotherapeutics: Base-Case Q3 Report Keeps 'Show Me' Mode [Seeking Alpha]
11/7
07:07 pm
iova
Is Iovance Biotherapeutics (IOVA) Undervalued? A Fresh Look at Valuation After Recent Share Price Rebound [Yahoo! Finance]
Low
Report
Is Iovance Biotherapeutics (IOVA) Undervalued? A Fresh Look at Valuation After Recent Share Price Rebound [Yahoo! Finance]
11/6
06:19 pm
iova
Iovance Biotherapeutics (NASDAQ:IOVA) had its price target lowered by analysts at Chardan Capital from $20.00 to $17.00. They now have a "buy" rating on the stock.
Neutral
Report
Iovance Biotherapeutics (NASDAQ:IOVA) had its price target lowered by analysts at Chardan Capital from $20.00 to $17.00. They now have a "buy" rating on the stock.
11/6
08:38 am
iova
Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results [Yahoo! Finance]
Low
Report
Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results [Yahoo! Finance]
11/6
08:00 am
iova
Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results
High
Report
Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results
11/3
07:00 am
iova
Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)
Low
Report
Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)
10/29
01:47 pm
iova
Iovance Biotherapeutics (NASDAQ:IOVA) had its price target lowered by analysts at HC Wainwright from $20.00 to $9.00. They now have a "buy" rating on the stock.
Medium
Report
Iovance Biotherapeutics (NASDAQ:IOVA) had its price target lowered by analysts at HC Wainwright from $20.00 to $9.00. They now have a "buy" rating on the stock.
10/29
08:30 am
iova
Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
Medium
Report
Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
10/29
08:30 am
iova
Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
Medium
Report
Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
10/29
08:15 am
iova
IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders
Medium
Report
IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders
10/23
04:05 pm
iova
Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025
Low
Report
Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025
10/17
05:15 pm
iova
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Medium
Report
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
10/13
06:18 am
iova
Is Iovance Biotherapeutics Stock Your Ticket to Becoming a Millionaire? [Yahoo! Finance]
Low
Report
Is Iovance Biotherapeutics Stock Your Ticket to Becoming a Millionaire? [Yahoo! Finance]
10/8
03:05 pm
iova
IOVANCE (IOVA) ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Low
Report
IOVANCE (IOVA) ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
9/20
03:08 am
iova
Iovance Biotherapeutics, Inc. (IOVA) Targeting $1B on Amtagvi Sales amid Cost Cuts [Yahoo! Finance]
Low
Report
Iovance Biotherapeutics, Inc. (IOVA) Targeting $1B on Amtagvi Sales amid Cost Cuts [Yahoo! Finance]
9/19
05:17 pm
iova
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) [Yahoo! Finance]
9/19
05:00 pm
iova
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Low
Report
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
9/8
12:58 am
iova
H.C. Wainwright Keeps Buy Rating on Iovance (IOVA) After Health Canada Authorization News [Yahoo! Finance]
Medium
Report
H.C. Wainwright Keeps Buy Rating on Iovance (IOVA) After Health Canada Authorization News [Yahoo! Finance]